Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 12/20 | 0.57 |
| ▸ | AURKA | O14965 | 11/20 | 0.57 |
| ▸ | PLK4 | O00444 | 2/20 | 0.57 |
| ▸ | AURKC | Q9UQB9 | 2/20 | 0.57 |
| ▸ | ABL1 | P00519 | 2/20 | 0.57 |
| ▸ | BCR | P11274 | 2/20 | 0.57 |
| ▸ | SRC | P12931 | 2/20 | 0.57 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.57 |
| ▸ | STK25 | O00506 | 1/20 | 0.57 |
| ▸ | RIOK3 | O14730 | 1/20 | 0.57 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.57 |
| ▸ | GAK | O14976 | 1/20 | 0.57 |
| ▸ | MUSK | O15146 | 1/20 | 0.57 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.57 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.57 |
| ▸ | MAP3K13 | O43283 | 1/20 | 0.57 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.57 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.57 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.57 |
| ▸ | JAK2 | O60674 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12338887 | 0.91 | AURKA (0.57) | AURKBAURKAPLK4AURKCABL1 | |
| SCHEMBL12338839 | 0.88 | AURKB (0.74) | AURKBAURKAPLK4AURKCABL1 | |
| SCHEMBL12338855 | 0.87 | AURKA (0.61) | AURKBAURKAPLK4AURKCABL1 | |
| SCHEMBL12338845 | 0.86 | AURKB (0.63) | AURKBAURKAPLK4AURKCABL1 | |
| SCHEMBL12338889 | 0.86 | AURKA (0.64) | AURKBAURKAPLK4AURKCABL1 | |
| SCHEMBL12338842 | 0.86 | AURKB (0.60) | AURKBAURKAPLK4AURKCABL1 | |
| SCHEMBL12338907 | 0.85 | AURKB (0.62) | AURKBAURKAPLK4AURKCABL1 | |
| SCHEMBL12341452 | 0.85 | AURKB (0.61) | AURKBAURKAPLK4AURKCABL1 | |
| SCHEMBL12338882 | 0.85 | AURKB (0.65) | AURKBAURKAPLK4AURKCABL1 | |
| SCHEMBL12338852 | 0.85 | AURKA (0.70) | AURKBAURKAPLK4AURKCABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382229-B2 | Compounds and methods of use thereof for treating neurodegenerative disorders | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-07-05 | — | — | US | disclosed |
| US-8779127-B2 | Processes for preparing substituted pyrimidines | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-07-15 | — | — | US | disclosed |
| US-20140187540-A1 | COMPOUNDS AND METHODS OF USE THEREOF FOR TREATING NEURODEGENERATIVE DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-07-03 | — | — | US | disclosed |
| US-20130066069-A1 | PROCESSES FOR PREPARING SUBSTITUTED PYRIMIDINES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-14 | — | — | US | disclosed |
| US-8268829-B2 | Substituted pyrimidines useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268829-B2 | Substituted pyrimidines useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20090221602-A1 | PROCESSES FOR PREPARING SUBSTITUTED PYRIMIDINES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-09-03 | — | — | US | disclosed |
| US-20090221602-A1 | PROCESSES FOR PREPARING SUBSTITUTED PYRIMIDINES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-09-03 | — | — | US | disclosed |
| US-7557106-B2 | Substituted pyrimidines useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557106-B2 | Substituted pyrimidines useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140187540-A1 | COMPOUNDS AND METHODS OF USE THEREOF FOR TREATING NEURODEGENERATIVE DISORDERS | CLN6, NLN, HTT | AURKB 4124/4885AURKA 4696/4885PLK4 2921/4885 |
| US-20090221602-A1 | PROCESSES FOR PREPARING SUBSTITUTED PYRIMIDINES | AURKA, AURKC, AURKB | AURKB 3/4885AURKA 1/4885PLK4 61/4885 |
| US-20130066069-A1 | PROCESSES FOR PREPARING SUBSTITUTED PYRIMIDINES | AURKA, AURKC, AURKB | AURKB 3/4885AURKA 1/4885PLK4 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.